Search

Your search keyword '"Tárraga L"' showing total 165 results

Search Constraints

Start Over You searched for: Author "Tárraga L" Remove constraint Author: "Tárraga L"
165 results on '"Tárraga L"'

Search Results

1. Cognitive plasticity in normal and pathological aging

2. Evaluation of the Feasibility, Safety and Efficacy of the Use of Intravenous Infusions of Adenosine Triphosphate (ATP) in People Affected by Moderate to Severe Alzheimer’s Disease: A Double-Blind Masked Clinical Trial for Dose Finding

3. A novel Alzheimer disease locus located near the gene encoding tau protein.

4. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

6. Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results

8. New insights into the genetic etiology of Alzheimer's disease and related dementias

9. Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

11. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

12. New insights into the genetic etiology of Alzheimer's disease and related dementias

13. Genome-wide significant risk factors for Alzheimerʼs disease: role in progression to dementia due to Alzheimerʼs disease among subjects with mild cognitive impairment

14. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

15. ATP5H/KCTD2 locus is associated with Alzheimerʼs disease risk

16. 1st Conference Clinical Trials on Alzheimer’s Disease September 17-18-19, 2008 School of Medecine Montpellier, France

17. A novel Alzheimer disease locus located near the gene encoding tau protein

18. Plasma Aß42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

22. Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease

23. Exploring APOE genotype effects on Alzheimer's disease risk and amyloid beta burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results

24. Correction: Genetic risk for schizophrenia and psychosis in Alzheimer disease

25. PLASMA A?42/40 RATIO DETECTS EARLY STAGES OF ALZHEIMER’S DISEASE AND CORRELATES WITH CSF AND NEUROIMAGING BIOMARKERS IN THE AB255 STUDY

26. Genetic risk for schizophrenia and psychosis in Alzheimer disease

27. Follow-up of loci from the International Genomics of Alzheimer's Disease Project identifies TRIP4 as a novel susceptibility gene

28. Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia

29. Genome-wide significant risk factors for Alzheimer’s disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment

30. Applications of telemedicine in the integral management of chronic obstructive pulmonary disease: systematic review

31. Estudio farmacoeconómico del tratamiento antitabáquico en un entorno clínico en Albacete.

32. A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer's disease.

34. Learning potential: a new method for assessing cognitive impairment.

35. Unidad de tabaquismo de Albacete

36. Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD): validación española.

37. Neuropsychiatric Inventory-Nursing Home version (NPI-NH): validación española.

39. Macular vessel density in the superficial plexus is not a proxy of cerebrovascular damage in non-demented individuals: data from the NORFACE cohort.

40. Genome-wide association study and polygenic risk scores of retinal thickness across the cognitive continuum: data from the NORFACE cohort.

41. Unveiling the sound of the cognitive status: Machine Learning-based speech analysis in the Alzheimer's disease spectrum.

42. An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response.

43. Harnessing acoustic speech parameters to decipher amyloid status in individuals with mild cognitive impairment.

44. A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress.

45. Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer's disease in individuals with mild cognitive impairment: The NORFACE cohort.

46. Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment.

47. The Synergic Effect of AT(N) Profiles and Depression on the Risk of Conversion to Dementia in Patients with Mild Cognitive Impairment.

48. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.

49. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers.

50. Differences in macular vessel density in the superficial plexus across cognitive impairment: the NORFACE cohort.

Catalog

Books, media, physical & digital resources